Boundless Bio, Inc.
BOLD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BOLD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BOLD
Boundless Bio is a clinical-stage biotechnology company developing ecDNA-directed therapeutics (ecDTx) for oncogene-amplified cancers, with a lead program BBI-940 and a proprietary Spyglass platform.
Key risk: Novel and unproven approach
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 3 clinical trials for Boundless Bio, Inc..
Boundless Bio is a clinical-stage biotechnology company developing ecDNA-directed therapeutics (ecDTx) for oncogene-amplified cancers, with a lead program BBI-940 and a proprietary Spyglass platform.
- Boundless Bio focuses on ecDNA-directed therapeutics (ecDTx) for oncogene-amplified cancers [sec · filed 2025-05-23].
- As of June 30, 2026, the company had cash, cash equivalents, and short-term investments of $72.6 million [sec_mda · as of 2026-08-07].
- The company reported a net loss of $23.7M for the period ending June 30, 2026, and an accumulated deficit of $273.2 million as of March 31, 2026 [sec_mda · as of 2026-05-08].
- Boundless Bio has streamlined operations, including a workforce reduction completed in September 2025, to extend cash runway through proof-of-concept readouts for its programs [sec_mda · as of 2025-11-05].
- The lead candidate BBI-940 is a Kinesin program, and the company has discontinued dose escalation of BBI-825 after preliminary pharmacokinetic data [sec_mda · as of 2025-11-05].
What works
- The company has a novel approach targeting ecDNA, a distinct mechanism in oncogene-amplified cancers, with a proprietary Spyglass platform to inform development [sec_mda · as of 2026-05-08].
- Management has taken proactive steps to prioritize resources, focusing on BBI-940 and streamlining operations to extend cash runway through key proof-of-concept data readouts [sec_mda · as of 2025-11-05].
- As of June 30, 2026, the company held $72.6 million in cash, cash equivalents, and short-term investments, providing a runway into the first half of 2028 based on prior operating plans [sec_mda · as of 2026-08-07].
What to weigh
- The company has incurred significant operating losses since inception, with an accumulated deficit of $273.2 million as of March 31, 2026, and expects losses to increase [sec_mda · as of 2026-05-08].
- The ecDTx approach is novel and unproven, and results from preclinical studies or early clinical trials may not be predictive of future results [sec · filed 2025-05-23].
- The company discontinued its BBI-825 program after preliminary pharmacokinetic data, highlighting the risk of clinical-stage setbacks [sec_mda · as of 2025-11-05].
- Cash burn remains high, with a net loss of $23.7M in the latest quarter, and the company may need additional financing to support operations beyond its current runway [sec_mda · as of 2026-08-07].
From the filings
Quoted directly from source documents.
The company's approach to ecDNA-directed therapeutics is novel and unproven.
“the Company is early in its development efforts and its approach to discover and develop ecDTx to treat oncogene amplified cancers is novel and unproven”
SEC filings · May 23, 2025
As of March 31, 2026, the company had an accumulated deficit of $273.2 million.
“as of March 31, 2026, we had an accumulated deficit of $273.2 million”
SEC MD&A · May 8, 2026
The company discontinued dose escalation of BBI-825 after preliminary pharmacokinetic data.
“we announced our decision not to continue dose escalation of Part 1 or to proceed into the Part 2 portion of our clinical trial of BBI-825”
SEC MD&A · November 5, 2025
As of June 30, 2026, the company had $72.6 million in cash, cash equivalents, and short-term investments.
“As of June 30, 2026, we had cash, cash equivalents, and short-term investments of $72.6 million”
SEC MD&A · August 7, 2026
Risks & what to watch (4)›
Key risks
- Novel and unproven approach — ecDTx approach is early-stage and unproven; preclinical results may not predict clinical outcomes [sec · filed 2025-05-23].
- Significant accumulated losses — Accumulated deficit of $273.2M as of March 31, 2026; expects losses to increase [sec_mda · as of 2026-05-08].
- Clinical program discontinuation — Discontinued BBI-825 after preliminary PK data, indicating clinical risk [sec_mda · as of 2025-11-05].
- Cash burn and financing need — Net loss of $23.7M in latest quarter; may need additional capital beyond current runway [sec_mda · as of 2026-08-07].
What to watch
- Proof-of-concept clinical data readouts for BBI-940 and other programs [sec · filed 2025-05-23].
- IND submission and initiation of clinical trial for BBI-940 [sec · filed 2025-05-23].
- Cash runway updates and potential need for additional financing [sec_mda · as of 2026-08-07].
- Regulatory and policy developments affecting FDA review timelines [sec_mda · as of 2025-11-05].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Boundless Bio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Boundless Bio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
10.1 months
D/E 0.12 · 0% dilution
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
22 buys · 2 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
33
Total value held
$8.8M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 2,695,455 | $3.0M |
| citadel advisors llc | 1,342,131 | $1.5M |
| vanguard capital management llc | 1,194,384 | $1.3M |
| sectoral asset management inc | 678,574 | $746K |
| wellington management group llp | 556,233 | $612K |
| renaissance technologies llc | 399,000 | $439K |
| alyeska investment group, l.p. | 300,000 | $330K |
| sio capital management, llc | 163,679 | $180K |
| geode capital management, llc | 127,576 | $140K |
| millennium management llc | 99,875 | $110K |
Showing top 10 of 33 institutional holders of Boundless Bio, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 1.1%
- Days to cover
- 0.4
- Shares short
- 145,151
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BOLD short interestGovernance
Frequently asked questions
What is the AI investment thesis for Boundless Bio, Inc.?
Boundless Bio is a clinical-stage biotechnology company developing ecDNA-directed therapeutics (ecDTx) for oncogene-amplified cancers, with a lead program BBI-940 and a proprietary Spyglass platform.
What is Boundless Bio, Inc.'s lead drug candidate?
Boundless Bio, Inc.'s most advanced tracked candidate is BBI-355 (Phase 1) for Triple Negative Breast Cancer (TNBC).
Who is the CEO of Boundless Bio, Inc.?
Mr. Zachary D. Hornby is the chief executive officer of Boundless Bio, Inc. (BOLD).
Where is Boundless Bio, Inc. headquartered?
Boundless Bio, Inc. (BOLD) is headquartered in San Diego, CA, United States.
What therapeutic areas does Boundless Bio, Inc. focus on?
Boundless Bio, Inc. develops therapies across Oncology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.